Anika Therapeutics Inc (NASDAQ:ANIK) Director Jeffery S. Thompson Sells 4,843 Shares

Share on StockTwits

Anika Therapeutics Inc (NASDAQ:ANIK) Director Jeffery S. Thompson sold 4,843 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $56.66, for a total transaction of $274,404.38. Following the sale, the director now owns 6,842 shares of the company’s stock, valued at $387,667.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Anika Therapeutics stock opened at $54.85 on Thursday. The company has a current ratio of 18.28, a quick ratio of 16.07 and a debt-to-equity ratio of 0.09. The business’s 50-day moving average price is $46.75. The stock has a market capitalization of $774.88 million, a price-to-earnings ratio of 27.42, a P/E/G ratio of 3.21 and a beta of 1.08. Anika Therapeutics Inc has a 1-year low of $29.01 and a 1-year high of $57.95.

Anika Therapeutics (NASDAQ:ANIK) last posted its earnings results on Wednesday, July 24th. The biotechnology company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.42 by $0.25. The company had revenue of $30.42 million during the quarter, compared to analyst estimates of $27.41 million. Anika Therapeutics had a net margin of 26.87% and a return on equity of 11.27%. Anika Therapeutics’s revenue for the quarter was down .4% on a year-over-year basis. During the same period in the prior year, the business posted $0.68 earnings per share. Sell-side analysts anticipate that Anika Therapeutics Inc will post 1.75 earnings per share for the current year.

Several analysts have issued reports on the stock. TheStreet upgraded shares of Anika Therapeutics from a “c” rating to a “b-” rating in a research report on Friday, July 26th. First Analysis upgraded shares of Anika Therapeutics from a “neutral” rating to a “strong-buy” rating and upped their price target for the company from $37.00 to $54.00 in a research report on Thursday, July 25th. ValuEngine upgraded shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, July 3rd. Barrington Research restated a “buy” rating and set a $49.00 price target (up from $45.00) on shares of Anika Therapeutics in a research report on Thursday, July 25th. Finally, Zacks Investment Research lowered shares of Anika Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, July 26th. Two analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Anika Therapeutics presently has an average rating of “Buy” and an average price target of $46.00.

Several institutional investors have recently bought and sold shares of the company. Texas Permanent School Fund boosted its holdings in shares of Anika Therapeutics by 3.8% during the first quarter. Texas Permanent School Fund now owns 9,649 shares of the biotechnology company’s stock worth $292,000 after purchasing an additional 349 shares during the period. Rhumbline Advisers boosted its holdings in shares of Anika Therapeutics by 0.9% during the first quarter. Rhumbline Advisers now owns 42,538 shares of the biotechnology company’s stock worth $1,286,000 after purchasing an additional 366 shares during the period. HL Financial Services LLC boosted its holdings in shares of Anika Therapeutics by 7.3% during the first quarter. HL Financial Services LLC now owns 6,988 shares of the biotechnology company’s stock worth $211,000 after purchasing an additional 475 shares during the period. State Board of Administration of Florida Retirement System boosted its holdings in shares of Anika Therapeutics by 5.3% during the second quarter. State Board of Administration of Florida Retirement System now owns 11,873 shares of the biotechnology company’s stock worth $482,000 after purchasing an additional 600 shares during the period. Finally, Swiss National Bank boosted its holdings in shares of Anika Therapeutics by 3.5% during the second quarter. Swiss National Bank now owns 26,400 shares of the biotechnology company’s stock worth $1,072,000 after purchasing an additional 900 shares during the period. Institutional investors own 97.95% of the company’s stock.

About Anika Therapeutics

Anika Therapeutics, Inc, together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology.

Featured Story: Beta

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Lido Advisors LLC Takes $230,000 Position in ISHARES TR/CORE DIVID GR ETF
Lido Advisors LLC Takes $230,000 Position in ISHARES TR/CORE DIVID GR ETF
Energy Income Partners LLC Buys 39,795 Shares of Mplx Lp
Energy Income Partners LLC Buys 39,795 Shares of Mplx Lp
Chesapeake Utilities Co.  Stock Position Decreased by Energy Income Partners LLC
Chesapeake Utilities Co. Stock Position Decreased by Energy Income Partners LLC
Family Management Corp Sells 4,840 Shares of Nuveen Municipal Value Fund Inc
Family Management Corp Sells 4,840 Shares of Nuveen Municipal Value Fund Inc
Energy Income Partners LLC Sells 21,934 Shares of IDACORP Inc
Energy Income Partners LLC Sells 21,934 Shares of IDACORP Inc
PGIM Global Short Duration Hgh Yd Fd Inc  Shares Bought by Family Management Corp
PGIM Global Short Duration Hgh Yd Fd Inc Shares Bought by Family Management Corp


© 2006-2019 Ticker Report